The new initiative of the Russian society of cardiosomatic rehabilitation and secondary prevention and the “Astra-Zeneca” pharmaceutical company
Main Author: | - - |
---|---|
Format: | Article |
Language: | English |
Published: |
Concilium Medicum
2016-06-01
|
Series: | КардиоСоматика |
Online Access: | https://cardiosomatics.orscience.ru/2221-7185/article/view/45261 |
Similar Items
-
The results of the 11th Russian Scientific-practical Conference of the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention with international participation "Rehabilitation and secondary prevention in cardiology"
by: - -
Published: (2015-06-01) -
EXPERT CONCLUSION OF THE SOCIETY OF CARDIOLOGY OF THE RUSSIAN FEDERATION, RUSSIAN NATIONAL SOCIETY OF ATHEROSCLEROSIS, RUSSIAN SOCIETY OF CARDIOSOMATIC REHABILITATION AND SECONDARY PREVENTION ON STATIN THERAPY OPTIMIZATION IN CLINICAL PRACTICE
Published: (2016-01-01) -
EXPERT CONCLUSION OF THE SOCIETY OF CARDIOLOGY OF THE RUSSIAN FEDERATION, RUSSIAN NATIONAL SOCIETY OF ATHEROSCLEROSIS, RUSSIAN SOCIETY OF CARDIOSOMATIC REHABILITATION AND SECONDARY PREVENTION ON STATIN THERAPY OPTIMIZATION IN CLINICAL PRACTICE
Published: (2016-01-01) -
Amyotrophic neuralgia secondary to Vaxzevri (AstraZeneca) COVID-19 vaccine
by: J.A. Crespo Burillo, et al.
Published: (2021-09-01) -
Effektivisering av orena lösningsmedelsströmmar på AstraZeneca
by: Goralski, Alma, et al.
Published: (2017)